What is the effect of zotuximab/veluoyi in the treatment of gastric cancer and its clinical manifestations

Zolbetuximab (zolbetuximab)-Vyloy is a monoclonal antibody targeting CLDN18.2, specifically used to treat patients with CLDN18.2-positive and HER2-negative locally advanced or metastatic gastric cancer and gastroesophageal junction cancer. This drug triggers the body's immune system to attack tumors by specifically binding to the tight junction protein CLDN18.2 on the surface of tumor cells, thereby providing additional anti-tumor effects on the basis of traditional chemotherapy. In clinical applications, zotuximab is often used in combination with standard chemotherapy regimens, such as mFOLFOX-6 or oxaliplatin and capecitabine, to provide patients with comprehensive treatment options.

In clinical studies, zotuximab has shown significant therapeutic advantages. In a study involving 565 patients, zotuximab plus mFOLFOX-6 was compared with placebo plus the same chemotherapy regimen. The results showed that patients who took zotuximab had a significantly longer time without disease progression, and their overall survival was also significantly better than that of the placebo group. Specifically, zotuximab can prolong the time patients remain in disease control and provide certain advantages in overall survival, demonstrating its potential to inhibit disease progression and improve prognosis in patients with advanced gastric cancer. This effect is not only reflected in disease control rate, but also in symptom relief and improvement in quality of life, allowing patients to maintain better daily activities during treatment.

In another studyof 507 patients, zotuximab showed a similar improvement in efficacy when combined with oxaliplatin and capecitabine. Compared with the placebo group, patients in the zotuximab group had improved time to disease progression and overall survival. The study also observed that in the context of combination chemotherapy, zotuximab can enhance the effect of chemotherapy and reduce tumor burden faster without significantly increasing intolerable toxic side effects. This suggests that zotuximab has good usability and safety in clinical practice, providing clinicians with new options when selecting treatment options.

Overall, the clinical performance of zotuximab in the treatment of gastric cancer is significant. Not only does it provide efficacy advantages in specific biomarker-positive patient populations, it also increases the overall efficacy of chemotherapy through immune system-mediated mechanisms. When patients receive zotuximab treatment, common clinical manifestations include symptom relief, improvement in quality of life, and delay in disease progression.

As a new type of targeted antibody drug, the introduction of zotuximab provides more treatment opportunities for patients with advanced gastric cancer, and also promotes the development of precision treatment concepts based on molecular markers in the field of gastric cancer. In the future, with the accumulation of more clinical practice and research data, zotuximab is expected to become an important treatment option for patients with CLDN18.2-positive gastric cancer worldwide, providing a reliable guarantee for improving prognosis and quality of life.

Reference materials:https://www.astellas.com/en/news/29401